Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.

Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM.

Diagnostics (Basel). 2017 Apr 21;7(2). pii: E23. doi: 10.3390/diagnostics7020023. Review.

2.

Primary pulmonary adenocarcinoma in a 16-year-old boy - a five-year follow-up.

Måreng AS, Langer SW, Bodtger U.

Eur Clin Respir J. 2016 Nov 7;3:32633. doi: 10.3402/ecrj.v3.32633. eCollection 2016.

3.

Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA).

Sommer MS, Trier K, Vibe-Petersen J, Christensen KB, Missel M, Christensen M, Larsen KR, Langer SW, Hendriksen C, Clementsen PF, Pedersen JH, Langberg H.

Integr Cancer Ther. 2016 Oct 3. pii: 1534735416668258. [Epub ahead of print]

PMID:
27698263
4.

[Cardiovascular complications following thoracic radiotherapy in patients with cancer].

Nielsen KM, Borchsenius JI, Offersen BV, Langer SW, Nielsen HM, Rasmussen VG, Hansen PR.

Ugeskr Laeger. 2016 Sep 26;178(39). pii: V05160362. Danish.

PMID:
27697124
5.

Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.

J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22.

PMID:
27660147
6.

Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.

Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, Binderup T, Kjaer A.

J Nucl Med. 2016 Dec;57(12):1851-1857. Epub 2016 Jul 28.

PMID:
27469355
7.

Perioperative Rehabilitation in Operable Lung Cancer Patients (PROLUCA): A Feasibility Study.

Sommer MS, Trier K, Vibe-Petersen J, Missel M, Christensen M, Larsen KR, Langer SW, Hendriksen C, Clementsen PF, Pedersen JH, Langberg H.

Integr Cancer Ther. 2016 Dec;15(4):455-466. Epub 2016 May 4.

PMID:
27151595
8.

(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

Olsen IH, Langer SW, Federspiel BH, Oxbøl J, Loft A, Berthelsen AK, Mortensen J, Oturai P, Knigge U, Kjær A.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):59-72. eCollection 2016.

9.

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U.

Diagnostics (Basel). 2015 Apr 8;5(2):119-76. doi: 10.3390/diagnostics5020119. Review.

10.

Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer.

Nygård L, Vogelius IR, Fischer BM, Klausen TL, Langer SW, Lonsdale MN, Persson GF, Bentzen SM.

Radiother Oncol. 2016 Mar;118(3):460-4. doi: 10.1016/j.radonc.2016.01.009. Epub 2016 Jan 21.

PMID:
26806265
11.

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases.

Langer SW, Ringholm L, Dali CI, Petersen RH, Rasmussen ÅK, Gerdes AM, Federspiel B, Knigge UP.

Case Rep Med. 2015;2015:265786. doi: 10.1155/2015/265786. Epub 2015 Dec 22.

12.

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H.

Ann Surg Oncol. 2016 May;23(5):1721-8. doi: 10.1245/s10434-015-5013-2. Epub 2015 Dec 17.

PMID:
26678407
13.

64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.

Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, Oturai P, Loft A, Hag AM, Kjær A.

J Nucl Med. 2015 Dec;56(12):1895-900. doi: 10.2967/jnumed.115.161216. Epub 2015 Oct 1.

14.

Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.

Tabaksblat EM, Langer SW, Knigge U, Grønbæk H, Mortensen J, Petersen RH, Federspiel BH, Ladekarl M.

Acta Oncol. 2016;55(1):3-14. doi: 10.3109/0284186X.2015.1067715. Epub 2015 Jul 30. Review.

PMID:
26223571
15.

64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.

Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A.

J Nucl Med. 2015 Jun;56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7.

16.
17.

The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy.

Quist M, Adamsen L, Rørth M, Laursen JH, Christensen KB, Langer SW.

Integr Cancer Ther. 2015 Jul;14(4):341-9. doi: 10.1177/1534735415572887. Epub 2015 Mar 22.

PMID:
25800229
18.

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients.

Olsen IH, Holt N, Langer SW, Hasselby JP, Grønbæk H, Hillingsø J, Mahmoud M, Ladekarl M, Iversen LH, Kjær A, Federspiel BH, Knigge U.

PLoS One. 2015 Feb 11;10(2):e0117627. doi: 10.1371/journal.pone.0117627. eCollection 2015.

19.

Dexrazoxane for the treatment of chemotherapy-related side effects.

Langer SW.

Cancer Manag Res. 2014 Sep 15;6:357-63. doi: 10.2147/CMAR.S47238. eCollection 2014. Review.

20.

Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas.

Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW.

J Cancer. 2014 Aug 1;5(8):628-32. doi: 10.7150/jca.9409. eCollection 2014.

Supplemental Content

Loading ...
Support Center